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A hemolytic transfusion reaction due to anti-Fy3 is reported in an
African American patient with no history of sickle cell disease. This
82-year-old African American woman received two units of RBCs for
anemia (Hb 7g/dL) on admission for a left hip fracture. On hospital
Day 7, the patient underwent left hip endoprosthesis surgery; she
received two units of RBCs on the second postoperative day due to
Hb of 6.1g/dL. Her urine was dark during surgery and
postoperatively. Her posttransfusion plasma was red. Her Hb
dropped from 8.4 to 6.4 g/dL over 24 hours after the transfusion.
Her total bilirubin rose to 4.0 mg/dL, with an LDH value of 1558
U/L and a haptoglobin of 10.9 mg/dL. Both the antibody detection
test and the DAT were positive. An anti-Fy3 was identified in the
serum and in the eluate. To the best of our knowledge, this is the
first case of acute intravascular hemolysis due to anti-Fy3 in a
patient without sickle cell disease. Immunohematology
2005;21:48–52.
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The Duffy blood group system bears the name of a
man with hemophilia who developed a novel antibody
after multiple blood transfusions.1 Two codominant
alleles, FYA and FYB, are located on chromosome 12,3
and encode the antithetical antigens, Fya and Fyb,
distinguished only by a single mutated residue at
position 42.3–6 The corresponding antisera, anti-Fya and
anti-Fyb, define four phenotypes: Fy(a+b+), Fy(a+b–),
Fy(a–b+), and Fy(a–b–). Additional high-prevalence
Duffy antigens include Fy3 and Fy6. These antigens are
recognized by monoclonal antibodies and have been
mapped to specific locations in the Duffy
glycopeptide. Thus, several anti-Fy3 monoclonal
antibodies have been described; they recognize either
a linear epitope on the third extracellular loop or a
conformational epitope formed by several extracellular
domains.7,8 Conversely, anti-Fy6 monoclonal antibodies
recognize an epitope in the N-terminal region,
upstream of the Fya/Fyb polymorphism.9,10 Of note, the
Fy6 antigenic determinant is defined by murine
monoclonal antibodies only, and no human polyclonal
antisera exist.8,9 Fy(a–b–) individuals lack both Fy3 and
Fy6 antigen expression on their RBCs. This Duffy-
negative phenotype is commonly found in West
Africans and African Americans.11,12 Most of these
individuals are genotypically FYB homozygotes
carrying a point mutation in the GATA-1 motif, which
specifically abolishes the transcriptional activity of
Duffy genes in the erythroid cells.13,14 However, the
Duffy transcript can still be found in various
extramedullary organs, expressed by the endothelial
cells of postcapillary venules.14 Therefore, it is thought
that such individuals with low levels of Fyb expression
in nonerythroid cells would not develop Fyb (or Fy3 or
both) antibodies when challenged with Fy(b+) RBCs.
Anti-Fy3 is a rare RBC alloantibody first described
by Albrey et al. in 1971.15 This initial case was an
Australian woman who, after receiving a blood
transfusion during her second pregnancy, delivered a
third baby with mild HDN. Investigation of her serum
during prenatal testing of her third pregnancy led to
the discovery of the antibody, and she was phenotyped
as Fy(a–b–).15 Subsequent reports have described the
same antibody in a Cree Indian woman and in other
Caucasian patients,16–18 all of them with a history of
transfusion or pregnancy. Interestingly, African
American individuals whose RBCs phenotype as
Fy(a–b–) usually develop anti-Fy3 after making anti-Fya
or other alloantibodies.19–22
We report a case of an African American patient
without sickle cell disease in whom solely anti-Fy3 was
shown to cause a severe hemolytic transfusion
reaction.
Case Report
An 82-year-old African American woman was
admitted to the hospital for elective repair of a left
femoral neck fracture. She had been in a motor vehicle
accident approximately two months previously, at
which time she sustained the injury and developed a
traumatic left femoral deep venous thrombosis (DVT).
She had been placed on Coumadin to treat the DVT. At
the time of the current admission (Day 0) she had
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heme-positive stools and anemia with a Hb of 7.5 g/dL
(baseline Hb 11 g/dL). (Table 1 summarizes the
patient’s laboratory data.)  Her antibody detection test
and DAT were negative. Her total bilirubin was 0.6
mg/dL. Her international normalized ratio (INR) was
subtherapeutic at 1.2. The Coumadin was discon-
tinued, and she received two units of RBCs on that day
(Day 0). Her posttransfusion Hb rose appropriately to
10.7 g/dL by Day 5, when she underwent
gastrointestinal endoscopy, which demonstrated only a
duodenal arteriovenous malformation which was
treated with heater probe.
On Day 7, the patient underwent endoprosthesis
surgery. Her preoperative Hb was 9.1 g/dL. When a
Foley catheter was inserted during surgery, grossly 
dark urine was noted in the Foley bag; this was
attributed to traumatic catheter placement. Through-
out the procedure, the patient had stable blood
pressure and pulse readings, and her maximum
temperature was 37.9°C. She had an estimated blood
loss of 300 mL. That night, the patient sustained a fever
of 38.2°C, but had no documented chills.
On Day 9 (postop day 2) the patient’s Hb was 6.1
g/dL; a drop thought due to recurrent gastrointestinal
bleeding. The patient was afebrile, and her vital signs
were stable. She was transfused with two units of
RBCs. One and one half hours after the transfusion of
the second unit, red urine was noted in the Foley bag.
Its analysis revealed free hemoglobin but no intact red
cells. Her temperature rose from 36.3°C to 37.2°C. At
this stage, hemolysis was suspected, and a workup
showed increased LDH at 1558 (reference range
100–190 U/L), decreased haptoglobin at 10.9 mg/dL
(reference range 16–200 mg/dL), and increased total
bilirubin at 4 mg/dL (reference range 0.2–1.3 mg/dL)
with a direct component of 0.4
mg/dL. The immunohematology
workup is described below. The
patient received intravenous
saline to maintain urine output of
approximately 200 mL/hr. The
patient did well, with no evi-
dence of renal dysfunction, and
her subsequent hospital course
was uncomplicated.
Materials and Methods
ABO and Rh typing as well as
antibody detection and identi-
fication tests were performed by
standard tube testing with LISS (Immucor, Inc.,
Norcross, GA) enhancement, using commercial
reagents according to the manufacturer’s protocol. The
DAT was performed with polyspecific antihuman
globulin and monospecific anti-IgG and anti-C3d
reagents (Gamma Biologicals, Inc., Houston, TX). The
patient’s serum was tested against panels of
commercial reagent RBCs (Gamma Biologicals, Inc.) to
determine antibody specificities. LISS (Immucor, Inc.)
and PEG (PeG™, Gamma Biologicals, Inc.) were used
as potentiating media. Patient’s serum and eluate
prepared by an acid elution method (ELU-KIT II™,
Gamma Biologicals, Inc.) were tested against panels of
commercially available reagent RBCs (Gamma
Biologicals, Inc. and Immucor, Inc.), and an inhouse
frozen RBC inventory for antibody identification. The
patient’s serum was also tested against ficin-treated
(Sigma, St. Louis, MO) RBCs, according to the AABB
Technical Manual (14th ed.) protocol.
Results
The patient’s antibody detection test was negative
on admission (Day 0) and she was transfused with two
units of crossmatch-compatible RBCs. On Day 9, she
was again transfused with two units of crossmatch-
compatible RBCs and, after transfusion of the second
unit, a hemolytic transfusion reaction was reported,
marked by red urine and a rise in temperature. The
DAT was 1+ with polyspecific reagent, weakly positive
with monospecific anti-C3d, and negative with anti-
IgG. The posttransfusion reaction antibody detection
test revealed a weak to 1+ reaction at the antiglobulin
phase with LISS enhancement. The antibody detection
test, performed on the pretransfusion sample, revealed
a weak to 1+ reaction with both LISS and PEG
Table 1. Laboratory values
Antibody 
Hospital Hb RBCs LDH Bilirubin (mg/dL) detection
day (g/dL) transfused (U/L) Total Direct DAT test
0 7.5 2 – 0.6 0.1 Negative Negative
1 9.3 – – – – – –
5 10.7 – – – – – –
6 9.6 – – – – – Positive
7 9.1 – – – – – –
9 6.1 2 – – – – –
8.4 – 1558 4.0 0.4 Positive (C3d) Anti-Fy3
10 6.4 – – – – – Anti-Fy3
15 9.3 – – – – – –
21 10.2 – – – – – –
enhancements. Additional studies in LISS revealed
positive reactions in 8 of 11 selected reagent RBCs at
the antiglobulin phase. Ten of 11 reagent RBCs were
positive, showing similar strengths of reactivity when
the serum-to-cell ratio was increased. The only RBC
that did not react was of the phenotype Fy(a–b–). This
agglutination pattern was confirmed on two separate
determinations with the same specimen. The eluate
was reactive (weakly positive) in 8 of 9 panel RBCs.
Once again, the only RBC that did not react was of the
phenotype Fy(a–b–). All other antibodies were
excluded using PEG enhancement. Serum tested
against additional Fy(a–b–) selected RBCs showed no
agglutination. When serum was tested against selected
Duffy-positive RBCs treated with ficin, reactivity was
seen in 9 of 9 RBCs at the antiglobulin phase. No
agglutination was seen at that phase in 5 of 5 Fy(a–b–)
ficin-treated RBCs. The presence of an anti-Fy3 was
confirmed by the AABB Reference Laboratory at
Gamma Biologicals (Houston, TX). The reference
laboratory had excluded anti-Fy5 by testing the serum
with Rhnull cells. The patient’s pretransfusion RBC
sample was phenotyped to be: D+, C–, E–, c+; M+, N+,
S–, s+; P1+; Le(a–b+); K–; Fy(a–b–); and Jk(a+b–). The
first unit of RBCs transfused upon admission was
Fy(a–b–); the second was Fy(a–b+). Both units
transfused postoperatively were Fy(a+b+), consistent
with the ensuing hemolysis.
Discussion
Albrey et al.15 first described anti-Fy3 after
investigating a prenatal serum of a pregnant woman.
Since that initial report, several other examples of anti-
Fy3 have been described.16–22 This is a clinically
significant antibody associated with mild HDN in two
offspring of the initially reported subjects.15,16
Additional cases of this antibody developing after
transfusion have been cited.18,20 In some of those
circumstances, it is not clear whether hemolytic
complications occurred, although some of the subjects
required blood transfusion. African American patients
who developed anti-Fy3, with or without signs and
symptoms of hemolysis, usually had concomitant
alloantibodies within the Duffy system, especially anti-
Fya.19,20,23
We are describing a patient who developed an
intravascular hemolysis due to anti-Fy3, in the absence
of any other alloantibody. This patient had a history of
RBC transfusion. She was phenotyped during the
current admission as Fy(a–b–). Fy(a–b–) is the
principal phenotype in West Africans and African
Americans and is characterized by the absence of Duffy
antigens on RBCs. This is thought to represent an
adaptive response to malarial infection, since
Plasmodium vivax requires the presence of the Duffy
antigen for RBC invasion.11,24–26 In West Africa, P. vivax
is conspicuously absent and 95 percent of individuals
are Fy(a–b–). The molecular mechanism underlying
this phenotype is thought to be the homozygosity for
an FYB allele with a point mutation in the promoter
region, which suppresses the expression of Duffy
glycopeptide in RBCs.13 However, Duffy antigens are
produced in several other locations, including the
endothelial cells of postcapillary venules and Purkinje
cells of the cerebellum,3,14,27 which would prevent the
formation of anti-Fyb and anti-Fy3 upon exposure to
Fy(b+) RBCs.
In contrast, cases of the Fy(a–b–) phenotype
described in Caucasians seem to be the result of a
different mechanism, involving deletion, frameshift, or
nonsense mutations in the open reading frame, while
the GATA-1 binding site remains unmutated.5,18 This
results in an unstable mRNA with premature
termination and lack of Duffy protein expression in all
cells. The absence of this protein does not seem to
have deleterious effects, even though it also functions
as a nonspecific receptor for chemokines and therefore
has been dubbed DARC (Duffy antigen receptor for
chemokines).11,28,29 DARC might act as an RBC surface
scavenger to eliminate excessive chemokines
produced under various pathologic circumstances30,31
and is likely an important player in the pathogenesis of
renal inflammation.32–34 Patients with this type of Duffy
gene silencing develop strong anti-Fy3.
In the case presented here, it is conceivable that a
similar process could have induced the formation of
anti-Fy3. While this is not the usual cause of the
Fy(a–b–) phenotype in African Americans, there are
several reports of the opposite phenomenon, in which
a GATA-1 motif mutation was responsible for the
Fy(a–b–) phenotype in Caucasian individuals.18 We
could not perform genotyping in this case to confirm
this hypothesis. It was not possible to test the patient’s
anti-Fy3 with cord RBCs. Such testing would have been
of interest because it is reported that anti-Fy3 made by
people with the Caucasian Fy(a–b–) phenotype reacts
strongly with cord RBCs, whereas that made by Blacks
reacts weakly or does not react with cord RBCs.
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